If approved by the Health Ministry, it would be the only once-daily single-tablet regimen for HIV infection in Japan, it said.

The drug contains JT's compound elvitegravir, which is used in Gilead Sciences Inc's Stribild regimen, approved by the US Food and Drug Administration in August 2012.

JT licensed elvitegravir to Gilead in 2005, giving Gilead exclusive rights to develop and commercialise the drug worldwide outside Japan.